{"id":7008,"date":"2025-02-28T10:46:18","date_gmt":"2025-02-28T10:46:18","guid":{"rendered":"https:\/\/itbusinesstoday.com\/?p=7008"},"modified":"2025-05-06T07:51:53","modified_gmt":"2025-05-06T07:51:53","slug":"eisai-enters-into-license-agreement-with-sciclone-for-development-and-commercialization-of-tasulgratinib-in-china-hong-kong-macau-and-taiwan","status":"publish","type":"post","link":"https:\/\/itbusinesstoday.com\/ja\/health-tech\/pharma\/eisai-enters-into-license-agreement-with-sciclone-for-development-and-commercialization-of-tasulgratinib-in-china-hong-kong-macau-and-taiwan\/","title":{"rendered":"\u4e2d\u56fd\u3001\u9999\u6e2f\u3001\u30de\u30ab\u30aa\u3001\u53f0\u6e7e\u306b\u304a\u3051\u308b\u30bf\u30b9\u30eb\u30b0\u30e9\u30c1\u30cb\u30d6\u306e\u958b\u767a\u304a\u3088\u3073\u5546\u696d\u5316\u306b\u95a2\u3059\u308b\u30b5\u30a4\u30af\u30ed\u30f3\u793e\u3068\u306e\u30e9\u30a4\u30bb\u30f3\u30b9\u5951\u7d04\u7de0\u7d50\u306b\u3064\u3044\u3066"},"content":{"rendered":"<?xml encoding=\"utf-8\" ?><p>\u30a8\u30fc\u30b6\u30a4\u682a\u5f0f\u4f1a\u793e\uff08\u672c\u793e\uff1a\u6771\u4eac\u90fd\u3001\u793e\u9577\uff1a\u5185\u85e4\u6674\u592b\uff09\u306f\u3001\u81ea\u793e\u5275\u88fd\u306e\u9078\u629e\u7684\u7dda\u7dad\u82bd\u7d30\u80de\u5897\u6b96\u56e0\u5b50\u53d7\u5bb9\u4f53\uff08FGFR\uff09\u30c1\u30ed\u30b7\u30f3\u30ad\u30ca\u30fc\u30bc\u963b\u5bb3\u5264\u3067\u3042\u308b\u30b3\u30cf\u30af\u9178\u30bf\u30b9\u30eb\u30b0\u30e9\u30c1\u30cb\u30d6\u306b\u3064\u3044\u3066\u3001\u4e2d\u56fd\u3001\u9999\u6e2f\u3001\u30de\u30ab\u30aa\u3001\u53f0\u6e7e\u306b\u304a\u3051\u308b\u72ec\u5360\u7684\u958b\u767a\u30fb\u8ca9\u58f2\u6a29\u3092\u4ed8\u4e0e\u3059\u308b\u30e9\u30a4\u30bb\u30f3\u30b9\u5951\u7d04\u3092SciClone Pharmaceuticals Limited\u3068\u7de0\u7d50\u3057\u307e\u3057\u305f\u3002 <a href=\"https:\/\/www.eisai.com\/\" data-no-translation=\"\">Eisai<\/a> \u306f\u3001\u30bf\u30b9\u30eb\u30b0\u30e9\u30c1\u30cb\u30d6\u306b\u95a2\u3059\u308b\u5168\u4e16\u754c\u3067\u306e\u6a29\u5229\u3092\u4fdd\u6301\u3057\u3001\u65e2\u306b\u4e0a\u5e02\u3055\u308c\u3066\u3044\u308b\u65e5\u672c\u3067\u306f\u5f15\u304d\u7d9a\u304d\u88fd\u9020\u30fb\u8ca9\u58f2\u3092\u884c\u3044\u307e\u3059\u3002<\/p><p>\u672c\u5951\u7d04\u306b\u57fa\u3065\u304d\u3001\u5f53\u793e\u306f\u5951\u7d04\u4e00\u6642\u91d1\u3001\u958b\u767a\u304a\u3088\u3073\u898f\u5236\u4e0a\u306e\u30de\u30a4\u30eb\u30b9\u30c8\u30f3\u3001\u767a\u58f2\u5f8c\u306f\u8ca9\u58f2\u30de\u30a4\u30eb\u30b9\u30c8\u30f3\u304a\u3088\u3073\u8ca9\u58f2\u53ce\u5165\u306b\u5fdc\u3058\u305f\u4e00\u5b9a\u306e\u30ed\u30a4\u30e4\u30eb\u30c6\u30a3\u3092\u53d7\u3051\u53d6\u308a\u307e\u3059\u3002<\/p><h4><strong>\u3053\u3061\u3089\u3082\u304a\u8aad\u307f\u304f\u3060\u3055\u3044\uff1a <a class=\"p-url\" href=\"https:\/\/itbusinesstoday.com\/ja\/health-tech\/pharma\/cardinal-health-co-ltd-launches-latest-enteral-nutrition-pump\/\" rel=\"bookmark\">\u30ab\u30fc\u30c7\u30a3\u30ca\u30eb\u30fb\u30d8\u30eb\u30b9\u682a\u5f0f\u4f1a\u793e\u304c\u6700\u65b0\u306e\u7d4c\u8178\u6804\u990a\u30dd\u30f3\u30d7\u3092\u767a\u58f2<\/a><\/strong><\/h4><p>Taslugratinib is a novel orally administered tyrosine kinase inhibitor that exhibits selective inhibitory activity against FGFR1, FGFR2, and FGFR3. In Japan, the drug has been approved for the treatment of &ldquo;FGFR2 fusion gene-positive, unresectable biliary tract cancer that has progressed after chemotherapy,&rdquo; and has been on the market since November 2024. In addition, a Phase I clinical trial for estrogen receptor-positive, HER2-negative breast cancer patients is currently underway in Japan.<\/p><p>\u30b5\u30a4\u30af\u30ed\u30f3\u306f\u3001\u304c\u3093\u304a\u3088\u3073\u91cd\u7be4\u306a\u611f\u67d3\u75c7\u6cbb\u7642\u85ac\u306e\u958b\u767a\u30fb\u5546\u696d\u5316\u306e\u305f\u3081\u306e\u7d71\u5408\u7684\u306a\u30d7\u30e9\u30c3\u30c8\u30d5\u30a9\u30fc\u30e0\u3092\u6709\u3059\u308b\u4e16\u754c\u7684\u306a\u30d0\u30a4\u30aa\u533b\u85ac\u54c1\u4f01\u696d\u3067\u3042\u308a\u3001\u4e2d\u83ef\u570f\u306b\u304a\u3044\u3066\u5f37\u529b\u306a\u30d7\u30ec\u30bc\u30f3\u30b9\u3092\u6709\u3057\u3066\u3044\u307e\u3059\u3002\u4eca\u56de\u306e\u30e9\u30a4\u30bb\u30f3\u30b9\u5951\u7d04\u306b\u3088\u308a\u3001\u30e9\u30a4\u30bb\u30f3\u30b9\u8a31\u8afe\u5730\u57df\u306b\u304a\u3044\u3066\u672c\u5264\u306e\u4fa1\u5024\u3092\u6700\u5927\u5316\u3057\u3001\u5fc5\u8981\u3068\u3057\u3066\u3044\u308b\u60a3\u8005\u3055\u3093\u306b\u4e00\u65e5\u3082\u65e9\u304f\u8ca2\u732e\u3057\u305f\u3044\u3068\u8003\u3048\u3066\u3044\u307e\u3059\u3002<\/p><p><strong>\u30bd\u30fc\u30b9 <a href=\"https:\/\/www.acnnewswire.com\/press-release\/japanese\/96516\/%E3%82%A8%E3%83%BC%E3%82%B6%E3%82%A4%E3%80%81%E7%B7%9A%E7%B6%AD%E8%8A%BD%E7%B4%B0%E8%83%9E%E5%A2%97%E6%AE%96%E5%9B%A0%E5%AD%90%E5%8F%97%E5%AE%B9%E4%BD%93%EF%BC%88fgfr%EF%BC%89%E9%81%B8%E6%8A%9E%E7%9A%84%E3%83%81%E3%83%AD%E3%82%B7%E3%83%B3%E3%82%AD%E3%83%8A%E3%83%BC%E3%82%BC%E9%98%BB%E5%AE%B3%E5%89%A4%E3%82%BF%E3%82%B9%E3%83%AB%E3%82%B0%E3%83%A9%E3%83%81%E3%83%8B%E3%83%96%E3%81%AB%E3%81%A4%E3%81%84%E3%81%A6%E4%B8%AD%E5%9B%BD%E3%83%BB%E9%A6%99%E6%B8%AF%E3%83%BB%E3%83%9E%E3%82%AB%E3%82%AA%E3%83%BB%E5%8F%B0%E6%B9%BE%E3%81%A7%E3%81%AE%E9%96%8B%E7%99%BA%E3%83%BB%E8%B2%A9%E5%A3%B2%E3%81%AB%E9%96%A2%E3%81%99%E3%82%8B%E3%83%A9%E3%82%A4%E3%82%BB%E3%83%B3%E3%82%B9%E5%A5%91%E7%B4%84%E3%82%92sciclone%E3%81%A8%E7%B7%A0%E7%B5%90\" data-no-translation=\"\">ACNNewsWire<\/a><\/strong><\/p>","protected":false},"excerpt":{"rendered":"<p>Eisai Co., Ltd. announced that it has signed a license agreement with SciClone Pharmaceuticals Limited to grant exclusive rights to develop and sell tasulgratinib succinate, an in-house developed selective fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitor, in China, Hong Kong, Macau and Taiwan. Eisai will retain the rights to tasulgratinib worldwide outside the license territory, and will continue to manufacture and sell the drug in Japan, where it has already been launched.Under this agreement, the Company will receive an upfront payment, as well as development and regulatory milestone payments, and, once launched, sales milestone payments and certain royalties based on sales revenue.Also Read: Cardinal Health Co., Ltd. launches latest [&hellip;]<\/p>\n","protected":false},"author":4,"featured_media":7044,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_bbp_topic_count":0,"_bbp_reply_count":0,"_bbp_total_topic_count":0,"_bbp_total_reply_count":0,"_bbp_voice_count":0,"_bbp_anonymous_reply_count":0,"_bbp_topic_count_hidden":0,"_bbp_reply_count_hidden":0,"_bbp_forum_subforum_count":0,"wprm-recipe-roundup-name":"","wprm-recipe-roundup-description":"","postBodyCss":"","postBodyMargin":[],"postBodyPadding":[],"postBodyBackground":{"backgroundType":"classic","gradient":""},"footnotes":""},"categories":[89,207,237,182],"tags":[1715,424,1716,1714,1713],"ppma_author":[205],"class_list":["post-7008","post","type-post","status-publish","format-standard","has-post-thumbnail","category-health-tech","category-international","category-news","category-pharma","tag-eisai","tag-pharma","tag-sciclone","tag-tasulgratinib","tag-tyrosine-kinase-inhibitor"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.2 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Eisai Licenses Tasulgratinib to SciClone for Greater China<\/title>\n<meta name=\"description\" content=\"Eisai has signed an agreement with SciClone Pharmaceuticals Limited to grant exclusive rights to develop and sell tasulgratinib succinate.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/itbusinesstoday.com\/ja\/health-tech\/eisai-enters-into-license-agreement-with-sciclone-for-development-and-commercialization-of-tasulgratinib-in-china-hong-kong-macau-and-taiwan\/\" \/>\n<meta property=\"og:locale\" content=\"ja_JP\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Eisai Licenses Tasulgratinib to SciClone for Greater China\" \/>\n<meta property=\"og:description\" content=\"Eisai has signed an agreement with SciClone Pharmaceuticals Limited to grant exclusive rights to develop and sell tasulgratinib succinate.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/itbusinesstoday.com\/ja\/health-tech\/eisai-enters-into-license-agreement-with-sciclone-for-development-and-commercialization-of-tasulgratinib-in-china-hong-kong-macau-and-taiwan\/\" \/>\n<meta property=\"og:site_name\" content=\"itbusinesstoday\" \/>\n<meta property=\"article:published_time\" content=\"2025-02-28T10:46:18+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-05-06T07:51:53+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/itbusinesstoday.com\/wp-content\/uploads\/2025\/02\/Eisai-Enters-Into-License-Agreement-with-SciClone-for-Development-and-Commercialization-of-Tasulgratinib.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"800\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/webp\" \/>\n<meta name=\"author\" content=\"NewsDesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u57f7\u7b46\u8005\" \/>\n\t<meta name=\"twitter:data1\" content=\"NewsDesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"\u63a8\u5b9a\u8aad\u307f\u53d6\u308a\u6642\u9593\" \/>\n\t<meta name=\"twitter:data2\" content=\"2\u5206\" \/>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"\u30a8\u30fc\u30b6\u30a4\u3001SciClone\u793e\u306bTasulgratinib\u306e\u4e2d\u56fd\u306b\u304a\u3051\u308b\u30e9\u30a4\u30bb\u30f3\u30b9\u4f9b\u4e0e","description":"\u5f53\u793e\u306f\u3001SciClone Pharmaceuticals Limited\u3068\u3001\u30b3\u30cf\u30af\u9178\u30bf\u30b9\u30eb\u30b0\u30e9\u30c1\u30cb\u30d6\u306e\u72ec\u5360\u7684\u958b\u767a\u30fb\u8ca9\u58f2\u6a29\u3092\u8a31\u8afe\u3059\u308b\u5951\u7d04\u3092\u7de0\u7d50\u3057\u307e\u3057\u305f\u3002.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/itbusinesstoday.com\/ja\/health-tech\/eisai-enters-into-license-agreement-with-sciclone-for-development-and-commercialization-of-tasulgratinib-in-china-hong-kong-macau-and-taiwan\/","og_locale":"ja_JP","og_type":"article","og_title":"Eisai Licenses Tasulgratinib to SciClone for Greater China","og_description":"Eisai has signed an agreement with SciClone Pharmaceuticals Limited to grant exclusive rights to develop and sell tasulgratinib succinate.","og_url":"https:\/\/itbusinesstoday.com\/ja\/health-tech\/eisai-enters-into-license-agreement-with-sciclone-for-development-and-commercialization-of-tasulgratinib-in-china-hong-kong-macau-and-taiwan\/","og_site_name":"itbusinesstoday","article_published_time":"2025-02-28T10:46:18+00:00","article_modified_time":"2025-05-06T07:51:53+00:00","og_image":[{"width":1200,"height":800,"url":"https:\/\/itbusinesstoday.com\/wp-content\/uploads\/2025\/02\/Eisai-Enters-Into-License-Agreement-with-SciClone-for-Development-and-Commercialization-of-Tasulgratinib.webp","type":"image\/webp"}],"author":"NewsDesk","twitter_card":"summary_large_image","twitter_misc":{"\u57f7\u7b46\u8005":"NewsDesk","\u63a8\u5b9a\u8aad\u307f\u53d6\u308a\u6642\u9593":"2\u5206"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/itbusinesstoday.com\/health-tech\/eisai-enters-into-license-agreement-with-sciclone-for-development-and-commercialization-of-tasulgratinib-in-china-hong-kong-macau-and-taiwan\/#article","isPartOf":{"@id":"https:\/\/itbusinesstoday.com\/health-tech\/eisai-enters-into-license-agreement-with-sciclone-for-development-and-commercialization-of-tasulgratinib-in-china-hong-kong-macau-and-taiwan\/"},"author":{"name":"NewsDesk","@id":"https:\/\/itbusinesstoday-68b209.ingress-baronn.ewp.live\/#\/schema\/person\/d58d81f55e8acd257ab63d49fb4ea812"},"headline":"Eisai Enters Into License Agreement with SciClone for Development and Commercialization of Tasulgratinib in China, Hong Kong, Macau and Taiwan","datePublished":"2025-02-28T10:46:18+00:00","dateModified":"2025-05-06T07:51:53+00:00","mainEntityOfPage":{"@id":"https:\/\/itbusinesstoday.com\/health-tech\/eisai-enters-into-license-agreement-with-sciclone-for-development-and-commercialization-of-tasulgratinib-in-china-hong-kong-macau-and-taiwan\/"},"wordCount":265,"publisher":{"@id":"https:\/\/itbusinesstoday-68b209.ingress-baronn.ewp.live\/#organization"},"image":{"@id":"https:\/\/itbusinesstoday.com\/health-tech\/eisai-enters-into-license-agreement-with-sciclone-for-development-and-commercialization-of-tasulgratinib-in-china-hong-kong-macau-and-taiwan\/#primaryimage"},"thumbnailUrl":"https:\/\/itbusinesstoday.com\/wp-content\/uploads\/2025\/02\/Eisai-Enters-Into-License-Agreement-with-SciClone-for-Development-and-Commercialization-of-Tasulgratinib.webp","keywords":["Eisai","Pharma","SciClone","Tasulgratinib","tyrosine kinase inhibitor"],"articleSection":["Health Tech","International","News","Pharma"],"inLanguage":"ja"},{"@type":"WebPage","@id":"https:\/\/itbusinesstoday.com\/health-tech\/eisai-enters-into-license-agreement-with-sciclone-for-development-and-commercialization-of-tasulgratinib-in-china-hong-kong-macau-and-taiwan\/","url":"https:\/\/itbusinesstoday.com\/health-tech\/eisai-enters-into-license-agreement-with-sciclone-for-development-and-commercialization-of-tasulgratinib-in-china-hong-kong-macau-and-taiwan\/","name":"\u30a8\u30fc\u30b6\u30a4\u3001SciClone\u793e\u306bTasulgratinib\u306e\u4e2d\u56fd\u306b\u304a\u3051\u308b\u30e9\u30a4\u30bb\u30f3\u30b9\u4f9b\u4e0e","isPartOf":{"@id":"https:\/\/itbusinesstoday-68b209.ingress-baronn.ewp.live\/#website"},"primaryImageOfPage":{"@id":"https:\/\/itbusinesstoday.com\/health-tech\/eisai-enters-into-license-agreement-with-sciclone-for-development-and-commercialization-of-tasulgratinib-in-china-hong-kong-macau-and-taiwan\/#primaryimage"},"image":{"@id":"https:\/\/itbusinesstoday.com\/health-tech\/eisai-enters-into-license-agreement-with-sciclone-for-development-and-commercialization-of-tasulgratinib-in-china-hong-kong-macau-and-taiwan\/#primaryimage"},"thumbnailUrl":"https:\/\/itbusinesstoday.com\/wp-content\/uploads\/2025\/02\/Eisai-Enters-Into-License-Agreement-with-SciClone-for-Development-and-Commercialization-of-Tasulgratinib.webp","datePublished":"2025-02-28T10:46:18+00:00","dateModified":"2025-05-06T07:51:53+00:00","description":"\u5f53\u793e\u306f\u3001SciClone Pharmaceuticals Limited\u3068\u3001\u30b3\u30cf\u30af\u9178\u30bf\u30b9\u30eb\u30b0\u30e9\u30c1\u30cb\u30d6\u306e\u72ec\u5360\u7684\u958b\u767a\u30fb\u8ca9\u58f2\u6a29\u3092\u8a31\u8afe\u3059\u308b\u5951\u7d04\u3092\u7de0\u7d50\u3057\u307e\u3057\u305f\u3002.","breadcrumb":{"@id":"https:\/\/itbusinesstoday.com\/health-tech\/eisai-enters-into-license-agreement-with-sciclone-for-development-and-commercialization-of-tasulgratinib-in-china-hong-kong-macau-and-taiwan\/#breadcrumb"},"inLanguage":"ja","potentialAction":[{"@type":"ReadAction","target":["https:\/\/itbusinesstoday.com\/health-tech\/eisai-enters-into-license-agreement-with-sciclone-for-development-and-commercialization-of-tasulgratinib-in-china-hong-kong-macau-and-taiwan\/"]}]},{"@type":"ImageObject","inLanguage":"ja","@id":"https:\/\/itbusinesstoday.com\/health-tech\/eisai-enters-into-license-agreement-with-sciclone-for-development-and-commercialization-of-tasulgratinib-in-china-hong-kong-macau-and-taiwan\/#primaryimage","url":"https:\/\/itbusinesstoday.com\/wp-content\/uploads\/2025\/02\/Eisai-Enters-Into-License-Agreement-with-SciClone-for-Development-and-Commercialization-of-Tasulgratinib.webp","contentUrl":"https:\/\/itbusinesstoday.com\/wp-content\/uploads\/2025\/02\/Eisai-Enters-Into-License-Agreement-with-SciClone-for-Development-and-Commercialization-of-Tasulgratinib.webp","width":1200,"height":800,"caption":"Eisai"},{"@type":"BreadcrumbList","@id":"https:\/\/itbusinesstoday.com\/health-tech\/eisai-enters-into-license-agreement-with-sciclone-for-development-and-commercialization-of-tasulgratinib-in-china-hong-kong-macau-and-taiwan\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/itbusinesstoday.com\/"},{"@type":"ListItem","position":2,"name":"Eisai Enters Into License Agreement with SciClone for Development and Commercialization of Tasulgratinib in China, Hong Kong, Macau and Taiwan"}]},{"@type":"WebSite","@id":"https:\/\/itbusinesstoday-68b209.ingress-baronn.ewp.live\/#website","url":"https:\/\/itbusinesstoday-68b209.ingress-baronn.ewp.live\/","name":"\u30a4\u30c3\u30c8\u30d3\u30b8\u30cd\u30b9\u30c8\u30a5\u30c7\u30a4","description":"","publisher":{"@id":"https:\/\/itbusinesstoday-68b209.ingress-baronn.ewp.live\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/itbusinesstoday-68b209.ingress-baronn.ewp.live\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"ja"},{"@type":"Organization","@id":"https:\/\/itbusinesstoday-68b209.ingress-baronn.ewp.live\/#organization","name":"\u30a4\u30c3\u30c8\u30d3\u30b8\u30cd\u30b9\u30c8\u30a5\u30c7\u30a4","url":"https:\/\/itbusinesstoday-68b209.ingress-baronn.ewp.live\/","logo":{"@type":"ImageObject","inLanguage":"ja","@id":"https:\/\/itbusinesstoday-68b209.ingress-baronn.ewp.live\/#\/schema\/logo\/image\/","url":"https:\/\/itbusinesstoday.com\/wp-content\/uploads\/2025\/01\/Asset-1.png","contentUrl":"https:\/\/itbusinesstoday.com\/wp-content\/uploads\/2025\/01\/Asset-1.png","width":663,"height":275,"caption":"itbusinesstoday"},"image":{"@id":"https:\/\/itbusinesstoday-68b209.ingress-baronn.ewp.live\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/itbusinesstoday-68b209.ingress-baronn.ewp.live\/#\/schema\/person\/d58d81f55e8acd257ab63d49fb4ea812","name":"\u30cb\u30e5\u30fc\u30b9\u30c7\u30b9\u30af","image":{"@type":"ImageObject","inLanguage":"ja","@id":"https:\/\/itbusinesstoday.com\/wp-content\/uploads\/2025\/01\/it.png74f313ad3d6fa27a1eee85c30be63d03","url":"https:\/\/itbusinesstoday.com\/wp-content\/uploads\/2025\/01\/it.png","contentUrl":"https:\/\/itbusinesstoday.com\/wp-content\/uploads\/2025\/01\/it.png","caption":"NewsDesk"},"sameAs":["https:\/\/itbusinesstoday.com"],"url":"https:\/\/itbusinesstoday.com\/ja\/author\/newsdesk\/"}]}},"authors":[{"term_id":205,"user_id":4,"is_guest":0,"slug":"newsdesk","display_name":"NewsDesk","avatar_url":{"url":"https:\/\/itbusinesstoday.com\/wp-content\/uploads\/2025\/01\/it.png","url2x":"https:\/\/itbusinesstoday.com\/wp-content\/uploads\/2025\/01\/it.png"},"author_category":"","first_name":"NewsDesk","last_name":"","user_url":"https:\/\/itbusinesstoday.com","job_title":"","description":""}],"_links":{"self":[{"href":"https:\/\/itbusinesstoday.com\/ja\/wp-json\/wp\/v2\/posts\/7008","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/itbusinesstoday.com\/ja\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/itbusinesstoday.com\/ja\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/itbusinesstoday.com\/ja\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/itbusinesstoday.com\/ja\/wp-json\/wp\/v2\/comments?post=7008"}],"version-history":[{"count":2,"href":"https:\/\/itbusinesstoday.com\/ja\/wp-json\/wp\/v2\/posts\/7008\/revisions"}],"predecessor-version":[{"id":10777,"href":"https:\/\/itbusinesstoday.com\/ja\/wp-json\/wp\/v2\/posts\/7008\/revisions\/10777"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/itbusinesstoday.com\/ja\/wp-json\/wp\/v2\/media\/7044"}],"wp:attachment":[{"href":"https:\/\/itbusinesstoday.com\/ja\/wp-json\/wp\/v2\/media?parent=7008"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/itbusinesstoday.com\/ja\/wp-json\/wp\/v2\/categories?post=7008"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/itbusinesstoday.com\/ja\/wp-json\/wp\/v2\/tags?post=7008"},{"taxonomy":"author","embeddable":true,"href":"https:\/\/itbusinesstoday.com\/ja\/wp-json\/wp\/v2\/ppma_author?post=7008"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}